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intRoDuction
More than doing an exhaustive theoretical exposition, the 
authors preferred to explore the advantages of multipara-
metric MRI (mpMRI) in the management of prostate cancer 
within different clinical scenarios that both radiologists and 
urologists may face. The most up-to-date evidence of prostatic 
artery embolization (PAE) for symptomatic benign prostatic 
hyperplasia (BPH) will be reviewed. Management of patients 
with BPH, technical aspects of PAE, expected outcomes and 
level of evidence are reviewed with the most recent literature.
pRostate canceR
Multiparametric magnetic resonance imaging 
(mpMRI)
mpMRI of the prostate gland mpMRI combines morpho-
logical and functional sequences: axial, coronal, and sagittal 
high-resolution T2 weighted images (T2WI) are obtained to 
depict the zonal anatomy prostate and surrounding organs. 
An axial T1 weighted imaging (T1WI) sequence is typically 
obtained for whole pelvis analysis, allowing the identifica-
tion of prostatic hemorrhage, abnormal lymph nodes, and 
suspicious bone lesions. These morphological sequences 
are combined with diffusion-weighted imaging (DWI) and 
dynamic contrast-enhanced (DCE) images, two functional 
sequences that increase both sensitivity and specificity on 
detection and staging of prostate cancer. MR spectroscopy 
is no longer routinely used in prostate mpMRI.1–6 Table 1 
shows detailed technical parameters of our protocol on a 
3 T magnet.
The current use of high-quality flexible body coils and 
properly configured 3 T MRI systems makes endorectal 
coils unnecessary. Some disadvantages were recognized by 
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aBstRact
Multiparametric MRI (mpMRI) has proven to be an essential tool for diagnosis, post-treatment follow-up, aggressiveness 
assessment, and active surveillance of prostate cancer. Currently, this imaging technique is part of the daily practice in 
many oncological centres. This manuscript aims to review the use of mpMRI in the set of prostatic diseases, either malig-
nant or benign: mpMRI to detect and stage prostate cancer is discussed, as well as its use for active surveillance. Image-
guided ablation techniques for prostate cancer are also reviewed. The need to establish minimum acceptable technical 
parameters for prostate mpMRI, standardize reports, uniform terminology for describing imaging findings, and develop 
assessment categories that differentiate levels of suspicion for clinically significant prostate cancer led to the development 
of the Prostate Imaging Reporting and Data System that is reviewed. Special focus will also be given on the most up-to-
date evidence of prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH). Management of 
patients with BPH, technical aspects of PAE, expected outcomes and level of evidence are reviewed with the most recent 
literature. PAE is a challenging technique that requires dedicated anatomical knowledge and comprehensive embolization 
skills. PAE has been shown to be an effective minimally-invasive treatment option for symptomatic BPH patients, that can 
be viewed between medical therapy and surgery. PAE may be a good option for symptomatic BPH patients that do not 
want to be operated and can obviate the need for prostatic surgery in up to 80% of treated patients.
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many radiologists, including slowed workflow, increased patient 
discomfort, decreased patient adherence, and risk of rectal 
injury.7 The first version of Prostate Imaging Reporting and 
Data System (PI-RADS) was published by the European Society 
of Urogenital Radiology in 2012. In 2014 the second version 
(PI-RADSv 2) showed some upgrades that have been recently 
updated to PIRADSv. 2.1 8–10 . Table 2 resumes PI-RADSv. 2.1 
criteria.
2.2. detection of prostate cancer
The traditional blind transrectal ultrasound (TRUS) biopsy aims 
to sample the peripheral zone, where the majority of cancers 
arise. In many urological centers, TRUS biopsy gets two cores 
per sextant that may miss small, aggressive peripheral cancers, 
as well as transitional, central or fibromuscular tumors. On the 
other hand, non-significant peripheral tumors may be diag-
nosed, thus leading to unnecessary treatments.11–14 Screening 
strategies involving the use of mpMRI rather than TRUS biopsies 
have shown higher sensitivity and specificity in the diagnosis of 
prostate cancer. Moreover, patient morbidity showed an apparent 
significant decrease, not only during diagnosis—avoiding 
unnecessary repeated biopsies—but also while choosing treat-
ment—reducing overtreatment in low-risk cancers.15 One of the 
main advantages of mpMRI is then to identify suspicious lesions 
that might undergo guided biopsy. Since 40–60% of prostate 
tumors are invisible at the ultrasound, MRI guidance should also 
be considered for a more accurate biopsy. It may be performed 
either directly (in-bore biopsy) or indirectly (using fusion tech-
niques that overlap TRUS images and previously obtained MR 
images).16–20
In the set of cancer detection, mpMRI reports should always 
include PI-RADS classification. PI-RADS categories 1 and 2 
refer to normal and benign changes, respectively. On the other 
hand, in categories 4 and 5, clinically significant cancer is likely 
and highly likely to be present, respectively (Figure 1). A score 
of 3 includes indeterminate, equivocal findings. According 
to PI-RADSv. 2.1, the score assigned on the ADC map and at 
DWI with high b-values is the dominant parameter for periph-
eral zone lesions. However, for abnormalities in the transition 
zone, the evaluation is based primarily on the score assigned at 
T2WI. DCE sequences have now more limited importance in the 
overall assessment of the prostate and only remain useful in the 
evaluation of peripheral lesions that were given a score of 3 on 
DWI/ADC analysis. Those lesions will be considered positive at 
DCE-MRI if a focal abnormality with early and intense enhance-
ment is found, thus increasing the overall PI-RADS score from 
3 to 4.21,22
staging
The eighth TNM edition introduced some important exchanges 
on prostate cancer. Pathological organ-confined disease (after 
radical prostatectomy)—pT2—is no longer subdivided into 
pT2a, pT2b, or pT2c. However, the extent of involvement and 
laterality remain important topics to report in mpMRI since the 
evolution from whole-gland to minimally invasive focal thera-
pies depends on a more accurate location of prostatic tumors.23 
pT3a still refers to tumors with extra capsular extension (ECE) 
or microscopic invasion of the bladder neck. While ECE may be 
identified on staging MRI, microscopic invasion of the bladder 
neck is below its visibility threshold. Multiple criteria are used to 
detect ECE, including capsule bulging, obliteration of the recto-
prostatic angle, asymmetry of the neurovascular bundle, focal 
capsular retraction and or thickening, tumor/capsule contact 
greater than 15 mm, or the presence of tumoral nodules in fat 
surrounding tissues. Despite not being specifically included 
in the TNM system, the evaluation of neurovascular bundles 
is another key point for patients who are candidates to nerve-
sparing surgeries (like robotic-assisted radical laparoscopic pros-
tatectomy) (Figure 2). DWI and DCE increase the accuracy of 
MRI in the depiction of ECE (and more precisely neurovascular 
bundle invasion) once truthful protocols are used.24–29 T3b refers 
to the invasion of the seminal vesicles, typically seen as T2WI 
hypointense lesions, restrictive pattern on DWI and enhance-
ment on DCE images. Other findings like enlarged low-sig-
nal-intensity ejaculatory ducts and obliteration of the angle 
between the prostate and the seminal vesicle may be also seen.23
Nodal staging is also performed in routine mpMRI protocols. 
This remains a challenging and misunderstood field for radiol-
ogists since morphological and dimensional criteria still seem to 
be not enough. The utility of DWI for nodal staging needs more 
research and may be time-consuming in daily practice.30 Routine 
mpMRI protocols do not allow an accurate evaluation of bone, 
not only due to the lack of morphological sequences like fat satu-
rated T2WI or short tau inversion-recovery but also because the 
entire skeleton is not within the range of study. Whole body MRI 
protocols have been developed over the last years and seem to be 
Table 1. Acquisition protocol on a 3T magnet
−30 min protocol (including preparation and positioning);
−without an ERC;
−18-channel PPA;
−antiperistaltic drugs (Buscopan®, Glucagon®).
−T2WI; axial, sagittal, and coronal; 3,5 mm, no gap; FOV 200 mm; matrix 384 × 384;
−DWI and ADC map; axial; 3,5 mm, no gap; FOV 200 mm; matrix 116 × 116; b-values: 0, 50, 1200, and 1400 s/mm2;
−DCE-MRI; axial; 3,5 mm, no gap; FOV 260 mm; matrix 154 × 192; maximum temporal resolution 15 s following single dose of contrast agent with an 
injection rate of 3 ml s−1; 30–35 acquisitions during 5 min.
ADC, apparent diffusion coefficient; DCE, dynamic contrast-enhanced; DWI, diffusion-weighted imaging; ERC, endorectal coil; FOV, field of view; 
PPA, pelvic phased arrays; T2WI, T2 weighted imaging.
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very useful for bone staging in prostate cancer, achieving similar 
results when comparing to bone scintigraphy and other nuclear 
studies.31
Active surveillance
Active surveillance is an alternative management for patients 
with a low clinical stage based on digital rectal examination 
(DRE) of the prostate, favorable prostate-specific antigen (PSA) 
levels evolution, low biopsy tumor grade, and minor tumor 
volume. Strict guidelines are still missing and reported inclu-
sion criteria vary. Most urological departments consider active 
surveillance in males with low-risk non-metastatic prostate 
cancer (cT1–cT2; PSA <10 ng ml−1; and biopsy Gleason score of 
6).32–38 mpMRI can be used to detect clinically significant pros-
tate cancer in males on active surveillance. Specific criteria for 
progression are still requiring but some theoretical concepts may 
be applied, namely size increase of the index lesion, onset of other 
suspicious lesions and new signs of locally invasive disease. It is 
theoretically expectable that a decrease in ADC values within a 
lesion between two examinations corresponds to a histological 
upgrade of the tumor. However, the noted variability of ADC 
quantification across imaging platforms and institutions, as well 
as across different examinations in the same patient even within 
normal tissue (e.g. due to different positioning of the region of 
interest), hampers this evaluation. Thus, radiologists should 
verify the accuracy of quantitative ADC measurements on their 
own MR system (e.g. using phantoms) and compare their results 
with those derived from similar MR systems.36–42 Overall, it is 
clear that mpMRI is useful for monitoring of males on active 
surveillance, but there is not enough evidence that it may replace 
the repetition of standard biopsy to detect progression over 
time.36,37,43
Ablation procedures
Besides the lack of ionizing radiation, interventional MRI (iMRI) 
offers other interesting advantages: the capability to guide 
needles and devices in any orientation; the inherent high tissue 
contrast; the ability to measure tissue firmness and thermal 
distribution through modern sequences; the development of 
real-time sequences. However, some disadvantages should not 
be forgotten, like the need for expensive nonferromagnetic tools 
and the small apertures and long bores that are typically found in 
the majority of MRI systems.44,45 Some focal therapies may use 
MRI as a guiding-method, such as focal laser ablation, cryoabla-
tion, and high-intensity focused ultrasound (HIFU). These tech-
niques are clinically safe and effective, with few associated sexual 
and urinary side-effects. Despite being more commonly used 
in the initial treatment of prostate cancer, they may be theoret-
ically performed in post-surgical and post-RT local recurrences, 
whenever it is accessible.44 More specific technical details about 
each treatment are beyond the scope of this article.
Biochemical failure
PSA level remains the basis of follow-up after curative treatment, 
but the definition of biochemical failure differs between RP and 
external beam radiotherapy (EBRT). After RP, it is defined by 
two consecutive PSA values of >0.2 ng ml−1. After EBRT, with 
or without short-term hormonal manipulation, it is defined 
Figure 1. Axial images of a 75-year-old male with an elevated PSA level (19 ng ml−1) who had undergone three previous negative 
systematic TRUS-guided biopsies. A huge bilateral, irregularly shaped focal lesion is seen in the anterior transition and zone 
anterior fibromuscular stroma (white arrows), moderately hypointense on T2WI (a), very restrictive at high b-value (b) and dark 
on the ADC map (c). Because of its size (>15 mm), this lesion was assigned a PI-RADS 5. A MRI/ultrasound fusion-guided biopsy 
was performed and an adenocarcinoma, Gleason score of 8 (4 + 4), was diagnosed. ADC, apparent diffusion coefficient; T2WI,T2 
weighted imaging; PI-RADS, Prostate Imaging Reporting and Data System; PSA, prostate-specificantigen; TRUS, traditional blind 
transrectal ultrasound.
Figure 2. T2W axial images of a 63-year-old male with an 
elevated PSA level (8,4 ng ml−1). An ill-defined, hypointense 
lesion is seen in the right peripheral zone (white arrows). 
Local bulging and irregularity of the capsule are also seen, as 
well as thickening of neurovascular bundle (clearly depicted in 
comparison to the opposite side). Due to extracapsular exten-
sion (including neurovascular bundle invasion), this lesion was 
assigned a PI-RADS 5. A MRI/ultrasound fusion-guided biopsy 
was performed and an adenocarcinoma, Gleason score of 8 
(4 + 4), was diagnosed. PI-RADS, Prostate Imaging Reporting 
and Data System; PSA, prostate-specific antigen; T2W, T2 
weighted.
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by a PSA increase >2 ng ml−1 higher than the initial PSA nadir 
value.46,47
Local relapse after RP commonly appears in the retrovesical 
space and at the vesicourethral anastomosis. It is usually seen as 
an interruption of the normal hypointense ring of the bladder 
neck and vesicourethral anastomosis by a tumor with higher 
signal intensity on T2WI. Moreover, recurrence typically pres-
ents as early enhancing nodules on DCE images and as bright 
foci on DWI at high b-values. In these cases, current guidelines 
do not contemplate PI-RADS classification.47,48 After EBRT, 
fibrosis and changes on parenchymal vascularization modify the 
biological behavior of tumors and normal tissue. Typical zonal 
anatomy of the prostate is lost and diffuse low signal intensity 
is seen on T2WI, thus diminishing the contrast between tumor 
and irradiated tissue, which hampers recurrence detection on 
morphological sequences. Despite also being distorted by EBRT, 
DCE-MRI and DWI are more accurate than T2WI in the depic-
tion of parenchymal recurrence (Figure 3).47
There is no consensus on biochemical failure after transperi-
neal brachytherapy and other less invasive alternative treatment 
options like cryosurgery and HIFU. Recurrence semiology is 
similar to that of post-EBRT studies.47 After non-surgical ther-
apies like EBRT, brachytherapy, cryosurgery or HIFU, PI-RADS 
classification may be used and a guided biopsy may be performed 
if a suspicious lesion is found. Since post-treatment changes may 
mimic tumors, essentially on morphological sequences, it is not 
surprising if the number of PI-RADS 3 is higher than desirable.
pRostatic aRteRy eMBolization FoR 
Benign pRostatic hypeRplasia
Patient management
Even though BPH is a histologic diagnosis, most patients are 
diagnosed based on the presence of lower urinary tract symp-
toms (LUTS) and benign prostatic enlargement (BPE). Biopsy is 
usually performed to exclude malignancy as histologic findings 
of BPH are ubiquitous in the older male. BPE may cause bladder 
Figure 4. Right anterior oblique view digital subtraction 
angiogram showing the right prostatic artery (dashed arrows) 
arising from the superior vesical artery (arrow). Note the 
acute angulation of the prostatic origin.
Figure 5. Selective catheterization of the prostatic artery was 
not possible due to the acute angulation of the origin. Thus, 
coil placement was performed in the superior vesical artery 
(arrow) to redirect flow away from the bladder and into the 
prostatic artery (dashed arrows).
Figure 3. Axial images of a 66-year-old male with an elevated 
PSA level (5,3 ng ml−1) who had undergone EBRT 6 years before 
because of an adenocarcinoma of the prostate, Gleason score 
of 6 (3 + 3). An ill-defined lesion is seen in the right periph-
eral zone (white arrows), moderately hypointense on T2WI 
(a), very restrictive at high b-value (b), dark on the ADC map 
(c), and enhancing on DCE images (d). Due to local capsular 
irregularity, this lesion was assigned a PI-RADS 5. A MRI/ultra-
sound fusion-guided biopsy was performed and an adeno-
carcinoma, Gleason score of 7 (4 + 3), was diagnosed. ADC, 
apparent diffusion coefficient; DCE, dynamiccontrast-en-
hanced; EBRT, external beam radiotherapy; PI-RADS,Prostate 
Imaging Reporting and Data System; PSA, prostate-specific 
antigen; T2WI, T2 weightedimaging.
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outlet obstruction (BOO) and LUTS. Multidisciplinary evalua-
tion of patients with symptomatic BPH is paramount as clinical 
management of these patients may be complex. LUTS may be 
caused by many other etiologies as bladder dysfunction, bladder 
neck contractures, nocturnal polyuria, urethral stricture, malig-
nancy and nervous system dysfunction amongst others. The 
presence and severity of LUTS do not correlate with the pres-
ence of BOO or the size of the prostate. Thus, a patient may have 
BPH and have no LUTS or BOO. The severity of BOO should 
be evaluated with peak urinary flowrate (Qmax) and post-void 
residual volume (PVR) measurements in all patients with LUTS 
because it may lead to complications such as recurrent urinary 
tract infections, bladder stones, overflow incontinence, gross 
hematuria, hydronephrosis, acute urinary retention, and renal 
disease that prompt invasive treatment.49,50 However, LUTS and 
prostatic volume (PV) are the main drivers for seeking medical 
care, as BOO frequently does not worry the patients. When 
dealing with these patients there are three main goals: reduce 
LUTS, decrease PV and relieve BOO severity in order to provide 
symptom control and possibly prevent disease progression.
The presence and severity of LUTS should be quantified with 
validated questionnaires such as the international prostate 
symptom score (IPSS) that is a powerful tool to assess treat-
ment response. The IPSS score has an additional question 
regarding the quality of life (QoL) related to the LUTS that is 
very important as this is the main driver to opt for more invasive 
treatment approaches when QoL >4 points. The IPSS score does 
not diagnose the presence or severity of BOO, nor the cause of 
LUTS. Thus, it is important to exclude all potential non-prostatic 
causes of LUTS before invasive treatment options are pursued. It 
is also important to assess the presence and severity of BOO with 
uroflowmetry and bladder ultrasound to assess the Qmax and 
PVR. BPE should be accurately quantified with transrectal ultra-
sound and/or MR imaging to assess the PV reduction 1 month, 
6 months, 12 months and then yearly after intervention. In order 
to exclude malignancy, digital rectal examination (DRE), PSA 
and mpMRI should be performed and biopsy if PSA >4 ng ml−1 
and/or suspicious DRE/mpMR. Erectile and ejaculatory func-
tion and incontinence severity index (ISI) should be evaluated 
before and after prostatic interventions. Validated questionnaires 
as the international index of erectile function (IIEF) and the male 
sexual health questionnaire-ejaculation disorder (MSHQ-EjD) 
are proven useful tools.
Patient age, PV, IPSS/QoL, Qmax, PVR and PSA should all be 
considered when counseling patients with LUTS for PAE. Inclu-
sion criteria are: age above 40 years, PV greater than 40 cm3, 
IPSS >18 points and/or QoL >3 points, Qmax < 12 ml s−1, PVR 
<200 cm3 and PSA <4 ng ml−1. If Qmax > 12 ml s−1 and/or PVR 
Figure 6. Control angiogram after embolization of the pros-
tatic artery shows stasis in the prostatic artery (dashed 
arrows) and the protective coil in the superior vesical artery 
(arrow).
Figure 7. Selective angiogram of the left prostatic artery 
(arrow) in posteroanterior view showing a large anastomosis 
to the penile artery (dashed arrows).
Figure 8. Selective angiogram of the left prostatic artery 
(arrow) in posteroanterior view after coil blockage of the 
penile anastomosis (dashed arrow) depicting prostatic central 
gland opacification and no penile branches.
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>200 cm3, when there is clinical suspicion of neurological disease 
or diabetes, patients under 40 years of age or PV <40 cm3, invasive 
urodynamic testing should be performed to exclude non-pros-
tatic causes of LUTS. Exclusion criteria include: malignancy, 
large bladder stones (>4 cm) or diverticula (>5 cm), advanced 
atherosclerosis (severe stenosis or occlusion) and tortuosity 
(more than two angulations < 90°) of iliac arteries or non-visu-
alization of prostatic arteries (PAs) on pre-procedural CT angi-
ography (CTA), urinary tract infection or renal insufficiency due 
to prostatic obstruction. Medical therapy is a first-line treatment 
option before considering invasive treatments for LUTS and 
BPH. Generally, PAE may be considered for those patients refrac-
tory to medical therapy for more than 6 months, not wishing or 
not tolerating medical therapy. Acute urinary retention (AUR) is 
also a good indication for PAE, as these patients have very good 
outcomes with embolization. For AUR patients, only PV and 
PSA should be measured as the IPSS/QoL, IIEF, MSHQ-EjD or 
ISI scores and Qmax/PVR are not reliable.
Technical aspects
PAE is a challenging technique due to two main reasons: complex 
anatomy and tortuosity of the PAs that may be very challenging to 
selective catheterize. PAs are small, lack pathognomonic findings 
and the internal iliac artery has many other side branches. Thus, 
one can easily “get lost” inside the pelvic arteries looking for the 
PAs.51 The tortuous pelvic arterial anatomy and the presence of 
atherosclerosis in aging male patients are the main reasons for 
PAE being successful in only one pelvic side (unilateral PAE) 
in up to 15% of patients.52 Two or more PAs can be found in 
up to 40% of pelvic sides with the most frequent origins being 
the superior vesical artery (30%), the internal pudendal artery 
(30%), the anterior division of the internal iliac artery (15%) 
and the obturator artery (10%). Rare/variant PA origins in up 
to 15% of pelvic sides include: accessory pudendal arteries (2%), 
prostatorectal trunks (7%), superior gluteal (1%) and inferior 
gluteal arteries (4%), aberrant obturators (1%) and penile artery 
(<1%). In up to 60% of pelvic sides, anastomoses can be detected 
between the prostatic arterial bed and the surrounding organs 
including the penis, rectum, bladder and seminal vesicles that 
may lead to non-target embolization.51,53,54 To overcome these 
challenges, steep ipsilateral oblique views have been adopted for 
PAE procedures51,54 that may lead to high radiation exposure to 
both patients and interventionalists.55
Either pre-procedural CTA51 or intra procedural cone beam CT 
(CBCT)56,57 should be used to guide interventionalists during 
PAE. Both techniques are equally effective for identifying the 
PAs.58 CBCT can also be used to certify correct catheterization 
of the PAs and exclude anastomoses that may lead to non-target 
embolization.56,57 CTA, even with optimized protocols using 
sublingual glyceryl trinitrate59 fails to identify most anastomoses. 
CBCT data can also be used for automatic vessel detection anal-
ysis, obviating the need for extensive anatomical knowledge.60 
MRA has been recently validated to define the anatomy of 
the PAS with a sensitivity of 92%.61 When anastomoses to 
surrounding organs are identified, coil occlusion has been shown 
to be safe and effective to prevent non-target embolization62 or 
to redirect flow into the prostate (Figures 4–8). Relevant variants 
include accessory pudendal arteries, prostatorectal trunks and 
aberrant obturators that may be identified with pre-procedural 
CTA.51 Besides femoral access, radial access has also been shown 
to be safe and effective for PAE.62
The use of pre-shaped Swan-neck tip microcatheters ≤ 2.4 F are 
the first-line option for many experienced interventionalists in 
PAE. The vascular access is usually 5 F and the catheters used vary 
considerably. When using a femoral approach, the cross-over 
technique will be necessary and the Waltman loop frequently 
performed to allow bilateral embolization through a single 
femoral access. Regarding embolic preference, microspheres 
100–500 µm63 and PVA particles 100–300 µm64 have been shown 
to be safe and effective. The use of microspheres <300 µm has the 
potential to induce more adverse events and untargeted emboli-
zation with limited clinical benefit.63,65,66 We advise using micro-
spheres >300 µm or PVA particles 100–300 µm independently of 
prostate volume or presence of collaterals. No specific embolic 
agent has proven superiority.63–66 We use of 100–200 µg of 
intra-arterial nitroglycerin inside the PAs just before the start of 
embolization to avoid spasm and early stasis.
Expected outcomes
The main goals of PAE are: 1. LUTS relief; 2. PV reduction; 3. 
Relief of BOO with increase in Qmax and PVR reduction. Also, 
adverse events should be prospectively registered and classified 
alongside with the collection of the IIEF, MSHQ-EjD and ISI 
scores. The need for prostatic medication or surgery after PAE 
should also be assessed with long-term data. Meta-analyses have 
proved significant treatment efficacy of PAE with IPSS reduction 
from baseline of 12.93, 14.98, 15.00 points at 1, 3 and 6 months 
post-PAE (50%–70% symptomatic relief); QoL reduction from 
baseline of 2.17, 2.18, 2.15 and 2.49 points at 1, 3, 6 and 12 
months post-PAE.67 Mean PV reduction after PAE is approxi-
mately 15–30%, with changes from baseline of 15–30 cm3 at 1, 
3, 6 and 12 months post-PAE.67 The Qmax increase after PAE 
is approximately 4.66 to 5.82 mL s−1 at 1, 3, 6 and 12 months 
post-PAE (20%–50% increase) and the PVR decrease after PAE 
is approximately 62–85 mL at 1, 3, 6 and 12 months post-PAE.67 
PSA has also been shown to reduce significantly after PAE with 
mean decrease of 1.2 ng ml−1 (15%–20%). IIEF scores after PAE 
did not show significant changes from baseline,67 ejaculation has 
also been prospectively shown to be preserved after PAE68 and 
no reports of incontinence after PAE exist so far.
PAE is a very well-tolerated procedure with almost no pain and 
no nausea or vomiting associated. It is an ideal procedure to be 
performed on an outpatient setting with the main concern being 
the arterial access hemostasis that may be obliviated with the use 
of radial access or femoral closure devices. The overall adverse 
events rate of PAE is expected to be 33%, with the vast majority 
(99%) being minor complications that need neither specific 
medical or surgical treatment nor admission to the hospital. 
Most of these adverse events include the so-called post-PAE 
syndrome with frequency and burning sensation in the urethra 
in up to 40% of patients. Macroscopic hematuria may be present 
in 5.6%, hematospermia in 0.5% and rectal bleeding in 2.5% of 
patients in the first week post-PAE. These are the main adverse 
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events after PAE and subside with conservative measures 1–2 
weeks after PAE. Urinary tract infection has been reported in 
up to 7.6% of patients and AUR in 2.5% of patients after PAE.69 
Some patients (<3%) may experience central gland detachment 
with prostatic fragments inside the urethra or bladder that may 
prompt removal by cystoscopy.69 Major adverse events that have 
been reported include a case of radiation dermatitis and those 
related to non-target embolization (<3%) to the penis, bladder, 
rectum and seminal vesicles.67,69
Most clinical failures after PAE are patients that never responded 
to embolization (non-responders)—up to 80% of all patients, with 
the remainder 20% being patients that initially improved, but then 
had relapsing symptoms (relapsers).70 Therefore, it is important 
to identify patient/baseline predictors as well as technical predic-
tors of clinical success to help select the best candidates for PAE 
and exclude those with a low probability of success after PAE. 
Other useful tools to help predict treatment response include 
MRI, peak PSA and C-reactive protein values 24 h after PAE and 
contrast-enhanced ultrasonography.70–77 Younger patients (up to 
65 years of age) with acute urinary retention and baseline IPSS 
of less than 23 points have been identified as responding better 
to PAE.70 Baseline prostate volume has yielded conflicting results 
with some studies showing better outcomes with larger prostates 
as opposed to others failing to prove any advantage.69–80 A cut-off 
of minimum PV for PAE has been shown to have implications in 
treatment outcomes—patients with PV <40 cm3 have been shown 
to have significantly worse outcomes after PAE.75 Patients with PV 
increase due to a large proportional increase of the central gland 
have been shown to respond better to PAE.75 Also, patient with 
multiple large (>1 cm) adenomas in the central gland have been 
shown to respond better to PAE than those without adenomas. 
The median lobe and central gland of the prostate are the regions 
of the prostate that respond better to embolization with higher 
areas of ischemia and larger volume reductions.72 Quantifica-
tion parameters with mpMR including perfusion and diffusion 
parameters have failed to predict treatment outcomes after PAE.76 
However, the proportion and the volume of prostate ischemia 
measured with MR in the first month after PAE have been shown 
to correlate significantly with the PSA level 24 h after PAE and 
with clinical outcome.70 MR after PAE should be performed 
within the first month post-PAE as ischemia usually disappears 
afterwards. No studies to date have focused in comparing the MR 
features between unilateral and bilateral PAE. High C-reactive 
protein values 24 h after PAE have also been shown to predict a 
good clinical outcome.75 The technique of PAE also has impact 
on outcomes: bilateral PAE has better outcomes than unilateral 
PAE.52,70,77 Particle size is a debatable issue80 with some studies 
failing to prove better outcomes with smaller (<300 µm) micro-
spheres,63,65 whereas others have reported better outcomes.75,77 
Predictors of technical difficulty include older age, atheroscle-
rosis, tortuosity of pelvic vessels and PAs originating from the 
superior vesical artery.77,81 The interventionalist and the use of 
protective coil embolization have also been shown to significantly 
influence procedural times and radiation dose.77
Evidence
Table 3 shows some of the most relevant Phase II trials that have 
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of PAE and surgery94–98 are presented in Table 4. The prospective 
comparative trials comparing PAE and surgery have shown that 
LUTS relief is similar between the two techniques which has led 
to widespread adoption in the UK.99 However, the relief of BOO 
and PV reduction is more effective with prostatic surgery than 
PAE. The rate of adverse events is lower with PAE, and surgery 
induces a higher rate of multiple adverse events and more serious 
adverse events. Recovery from intervention is faster with PAE 
than with surgery. All of these aspects should be taken into 
consideration when counseling patients with LUTS for PAE. 
PAE is effective at relieving LUTS and may be a viable option for 
patients after failed medication therapy or not tolerating prostatic 
medication. PAE does not preclude future prostatic surgeries that 
can always be performed in case the patient does not improve or 
when severe BOO is still present after embolization. PAE is an 
effective minimally invasive treatment option for patients with 
LUTS that can be viewed between medical therapy and surgery. 
General adoption from most urological societies is still lacking, 
as PAE is viewed as an experimental technique needing more 
long-term data and comparative trials.50 PAE may be a good 
option for patients with LUTS that do not want to be operated 
and can obviate the need for prostatic surgery in up to 80% of 
treated patients.
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